404 / 1631
2 x BEACOPP esc
End of therapy and residual nodes > 2.5 cm:
PET positive:
Rx
PET negative:
Follow up
Centrally reviewed PET
4x
BEACOPP esc
4x
BrECADD
2 x BrECADD
HL, Hodgkin Lymphoma; GHSG, German Hodgkin Study Group; BV, brentuximab vedotin; BEACOPPesc, bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, prednisone; BrECADD, brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine,
dexamethasone; PET, positron emission tomography; RX, radiotherapy
HD21: GHSG Perspective
BV in advanced stage HL